Paris-based drug giant Sanofi-Aventis (NYSE: [[ticker:SNY]]) said today it has formed a multi-year research collaboration with Stanford University’s Bio-X program. Under the deal, a joint steering committee from both organizations will agree on funding terms for as many as five projects a year, according to a statement. Sanofi may also host postdoctoral fellows from Stanford, while Stanford faculty may invite Sanofi scientists to be visiting scholars to pursue research work on campus. Details on finances weren’t disclosed in today’s statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
